Logo image of ABEO

ABEONA THERAPEUTICS INC (ABEO) Stock Fundamental Analysis

USA - NASDAQ:ABEO - US00289Y2063 - Common Stock

5.5 USD
+0.12 (+2.23%)
Last: 10/20/2025, 8:00:00 PM
5.55 USD
+0.05 (+0.91%)
After Hours: 10/20/2025, 8:00:00 PM
Fundamental Rating

3

ABEO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. ABEO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ABEO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ABEO has reported negative net income.
ABEO had a negative operating cash flow in the past year.
In the past 5 years ABEO always reported negative net income.
In the past 5 years ABEO always reported negative operating cash flow.
ABEO Yearly Net Income VS EBIT VS OCF VS FCFABEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ABEO's Return On Assets of 23.25% is amongst the best of the industry. ABEO outperforms 97.19% of its industry peers.
ABEO has a Return On Equity of 34.99%. This is amongst the best in the industry. ABEO outperforms 97.94% of its industry peers.
Industry RankSector Rank
ROA 23.25%
ROE 34.99%
ROIC N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ABEO Yearly ROA, ROE, ROICABEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

ABEO's Profit Margin of 14310.50% is amongst the best of the industry. ABEO outperforms 99.81% of its industry peers.
ABEO does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 14310.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABEO Yearly Profit, Operating, Gross MarginsABEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
ABEO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ABEO has been increased compared to 5 years ago.
ABEO has a worse debt/assets ratio than last year.
ABEO Yearly Shares OutstandingABEO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ABEO Yearly Total Debt VS Total AssetsABEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ABEO has an Altman-Z score of -2.06. This is a bad value and indicates that ABEO is not financially healthy and even has some risk of bankruptcy.
ABEO has a Altman-Z score (-2.06) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.09 indicates that ABEO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.09, ABEO is doing worse than 62.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -2.06
ROIC/WACCN/A
WACC9.37%
ABEO Yearly LT Debt VS Equity VS FCFABEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

ABEO has a Current Ratio of 6.73. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
ABEO's Current ratio of 6.73 is fine compared to the rest of the industry. ABEO outperforms 67.79% of its industry peers.
A Quick Ratio of 6.65 indicates that ABEO has no problem at all paying its short term obligations.
ABEO has a better Quick ratio (6.65) than 67.60% of its industry peers.
Industry RankSector Rank
Current Ratio 6.73
Quick Ratio 6.65
ABEO Yearly Current Assets VS Current LiabilitesABEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.63% over the past year.
The Revenue for ABEO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)30.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-378.95%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ABEO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.58% yearly.
ABEO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 420.09% yearly.
EPS Next Y174.57%
EPS Next 2Y43.89%
EPS Next 3Y37.59%
EPS Next 5Y27.58%
Revenue Next Year27374.5%
Revenue Next 2Y3315.94%
Revenue Next 3Y1164.88%
Revenue Next 5Y420.09%

3.3 Evolution

ABEO Yearly Revenue VS EstimatesABEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ABEO Yearly EPS VS EstimatesABEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABEO. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 44.93 indicates a quite expensive valuation of ABEO.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ABEO indicates a rather cheap valuation: ABEO is cheaper than 89.70% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.18, ABEO is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 44.93
ABEO Price Earnings VS Forward Price EarningsABEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABEO Per share dataABEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

ABEO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ABEO's earnings are expected to grow with 37.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.89%
EPS Next 3Y37.59%

More info and screens

0

5. Dividend

5.1 Amount

ABEO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABEONA THERAPEUTICS INC

NASDAQ:ABEO (10/20/2025, 8:00:00 PM)

After market: 5.55 +0.05 (+0.91%)

5.5

+0.12 (+2.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners73.63%
Inst Owner Change-0.03%
Ins Owners5.63%
Ins Owner Change-6.29%
Market Cap282.04M
Analysts86.67
Price Target20.91 (280.18%)
Short Float %18.08%
Short Ratio11.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.37%
Min EPS beat(2)-36.14%
Max EPS beat(2)35.41%
EPS beat(4)2
Avg EPS beat(4)1.78%
Min EPS beat(4)-53.14%
Max EPS beat(4)60.97%
EPS beat(8)4
Avg EPS beat(8)-1.46%
EPS beat(12)7
Avg EPS beat(12)23.44%
EPS beat(16)9
Avg EPS beat(16)14.87%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-309.64%
EPS NY rev (1m)1425%
EPS NY rev (3m)405.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)9.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 44.93
P/S 705.1
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 1.72
EV/EBITDA N/A
EPS(TTM)-1.54
EYN/A
EPS(NY)0.12
Fwd EY2.23%
FCF(TTM)-1.39
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0.01
BVpS3.19
TBVpS3.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 23.25%
ROE 34.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 14310.5%
GM N/A
FCFM N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 172.41%
Cap/Sales 1328%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.73
Quick Ratio 6.65
Altman-Z -2.06
F-Score5
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)32.9%
Cap/Depr(5y)51.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-378.95%
EPS Next Y174.57%
EPS Next 2Y43.89%
EPS Next 3Y37.59%
EPS Next 5Y27.58%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year27374.5%
Revenue Next 2Y3315.94%
Revenue Next 3Y1164.88%
Revenue Next 5Y420.09%
EBIT growth 1Y-31.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-65.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-54.12%
OCF growth 3YN/A
OCF growth 5YN/A